Pharmaceuticals company Piramal Pharma announced Q2FY26 results Revenue from Operations: Rs 2,044 crore compared to Rs 2,242 crore during Q2FY25, change -9%. EBITDA: Rs 224 crore compared to Rs 403 crore during Q2FY25, change -44%. EBITDA Margin: 11% for Q2FY26. PAT: Rs -99 crore compared to Rs 23 crore during Q2FY25. Nandini Piramal, Chairperson, Piramal Pharma, said: “YoY growth in the CDMO Business was primarily impacted by inventory destocking in one large on-patent commercial product. Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflows and customer decision making during H1FY26. However, in the months of September and October 2025, we have seen a significant pick up in biopharma funding, which if sustains, should lend impetus to increased RFPs and orders going forward. Also, we are seeing strong customer interest for onshore offerings which bodes well for the investments we have made in our overseas sites. In our CHG business we further strengthened our leadership position in the US Sevoflurane market, while simultaneously working to obtain regulatory approvals for ex-US markets from our India plant. Our consumer business delivered healthy mid-teen growth, seamlessly collaborating with various stakeholders for smooth transition to new GST rates changes.” Result PDF